COMPASS Pathways Plc American Depository Shares (CMPS) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Nuvation Bio (NUVB) over the past year, gaining 73.8% versus a gain of 33.1%. Over five years, NUVB leads with a -48.2% price change compared with -64.4% for CMPS. Nuvation Bio is the larger company by market cap ($1.74 billion vs $1.59 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | NUVB |
|---|---|---|
| Share price | $11.47 | $4.95 |
| Market cap | $1.59B | $1.74B |
| 1-day change | -1.88% | +1.85% |
| YTD return | +66.23% | -44.75% |
| 1-year return | +73.79% | +33.06% |
| 5-year return | -64.40% | -48.17% |
| EPS (TTM) | $-3.76 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.90M |
| Revenue growth (YoY) | — | +698.96% |
| Net income (latest FY) | $-287.86M | $-204.63M |
| Operating margin | — | -338.72% |
| Net margin | — | -325.31% |
| 52-week high | $15.87 | $9.75 |
| 52-week low | $4.88 | $3.36 |
| Distance from 52-week high | -27.73% | -49.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +107.06% | +162.63% |
| Average volume | 3.04M | 5.65M |
| Shares outstanding | 138.48M | 350.12M |
| Employees | 156 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed NUVB by 40.7 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
CMPS vs NUVB FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Nuvation Bio?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.74B compared with $1.59B for COMPASS Pathways Plc American Depository Shares (CMPS).
Which stock has performed better over the past year, CMPS or NUVB?
CMPS returned +73.79% over the past 12 months, compared with +33.06% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.